Abstract
RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro. This inhibition is reversible by dialysis in vitro, which accounts for the dose-dependent duration of in vivo enzyme inhibition of 12–24 h. Moclobemide increases the content of serotonin, noradrenaline and dopamine in the brain, and decreases that of their deaminated metabolites. Its biochemical, neurological and behavioural effects indicate that it increases the extracellular concentration of the classic monoamine neurotransmitters/neuromodulators — in particular 5-HT. Potentiation of the cardiovascular effects of tyramine is less pronounced after taking moclobemide than after irreversible MAO-A inhibitors. Understanding of the physiological role of MAO and of the events that link inhibition of the enzyme with modulation of neuronal activities in the CNS remains incomplete. A major physiological role of intraneuronal MAO is to keep cytosolic amine concentration very low, to enable the neuronal monoamine carriers to produce a net inward transport of monoamines, and thereby to act as the first step in the termination of action of extracellular monoamines. MAO is likely to have a similar function in non-monoaminergic cells with respect to the monoamine carriers they contain. In addition to the classic monoamines, “trace” amines may become functionally active after MAO inhibition. An alternative role for MAO is that of a scavenger, preventing natural substrates from accumulating in monoaminergic neurons and interacting with storage, release, uptake and receptor function of monoamines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bielenberg GW, Burkhardt M (1990) 5-Hydroxytryptamine1A agonist. A new therapeutic principle for stroke treatment. Stroke 21 [suppl IV]:161–163
Bönisch H, Trendelenburg U (1988) The mechanism of action of indirectly acting sympathomimetic amines. Handbook of Experimental Pharmacology 90/I:247–277
Burkard WP, Kettler R, Da Prada M, Haefely WE (1988) Neurochemical profile of the antidepressant moclobemide, a reversible type A monoamine oxidase inhibitor with minimal tyramine maker RH (eds) Neurology and neurobiology, vol 42 B. A.R. Liss, New York, pp 168–171
Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W (1989a) Preclinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry 155 [suppl]:84–88
Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RKM, Wyss P-C, Haefely W (1989b) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:391–399
Carney JM (1986) Acute tryptophan pretreatment protects against behavioral changes caused by cerebral ischemia. Neurosci Lett 66:127–130
Cesura AM, Kettler R, Imhof R, Da Prada M (1992) Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology [suppl] 106:S15-S16
Da Prada M, Keller HH, Kettler R, Schaffner R, Pieri M, Burkard WP, Korn A, Haefely WE (1981) Ro 11-1163, a specific and short-acting MAO inhibitor with antidepressant properties. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase. Basic and clinical frontiers. Excerpta Medica, Elsevier, Amsterdam-Oxford-Princeton, pp 183–196
Da Prada M, Kettler R, Burkard WP, Haefely WE (1984) Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 137–154
Da Prada M, Zürcher G, Wüthrich I, Haefely WE (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm [suppl] 26:31–56
Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE (1989a) Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm [suppl] 28:5–20
Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989b) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400–414
Da Prada M, Keller HH, Kettler R (1989c) Vergleich des neuen MAO-A-Hemmers Moclobemid, Brofaromin und Toloxaton mit Tranylcypromin im Tierversuch: Bedeutung für die Praxis. Psychiatr Prax 16:18–24
Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss P-C, Kyburz E, Imhof R (1990a) From moclobemide to Ro 19-6327 and Ro41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl 29:279–292
Da Prada M, Kettler R, Keller HH, Burkard WP (1990b) Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide. Acta Psychiatr Scand [suppl] 360:103–105
Flack B, Hillarp N-A, Thieme G, Torp A (1962) Fluorescence of catecholamines and related compounds condensed with formaldehyde. J Histochem Cytochem 10:348–354
Fuxe K, Agnati LF (eds) (1990) Volume transmission in the brain. Raven Press, New York
Gleiter CH, Nilsson E, Antonin KH, Bieck PR (1990) Effect of MAO inhibitors (brofaromine, clorgyline and moclobemide) on human platelet MAO-B activity. Clin Pharmacol Ther 47:165
Graefe K-H, Bönisch H (1988) The transport of amines across the axonal membranes of noradrenergic and dopaminergic neurons. Handbook of Experimental Pharmacology 90/I:193–245
Keller HH, Kettler R, Keller G, Da Prada M (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Arch Pharmacol 335:12–20
Korn A, Da Prada M, Rafferberg W, Allen S, Gasic S (1988a) Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm [suppl] 26:57–71
Korn A, Da Prada M, Rafferberg W, Gasic S, Eichler HG (1988b) The effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 11:17–23
Kwan S-W, Bergeron JM, Abell CW (1992) Molecular properties of monoamine oxidases A and B. Psychopharmacology [suppl] 106:S1-S5
Kyburz E (1989) New developments in the field of monoamine oxidase inhibitors (MAO-I). In: van der Goot H, Pallos L, Timmerman H (eds) Trends in Medicinal Chemistry 88. Elsevier, Amsterdam, pp 523–542
Lorez HP, Harvey J, Blaszat G, Thomas B, Martin JR, Kettler R, Wybrecht R, Da Prada M (1990) Inhibition of type A monoamine oxidase of hypoxic rat brain results in neuroprotection. Eur J Neurosci 3:133
Martin JR, Schaffner R, Rumennik L, Vincent GP, Sepinwall J, Lorez H-P, Haefely WE (1989) Cognitive performance enhancing effects of the reversible MAO-inhibitor moclobemide in animals. In: Wurtman RJ, Corkin S, Growdon JH, Ritter-Walker E (eds) Alzheimer's disease. Center for Brain Sciences and Metabolism Charitable Trust, Cambridge, MA, pp 689–694
Paterson IA, Inorio AV, Boulton AA (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 55:1827–1837
Richards JG, Saura J, Ulrich J, Da Prada M (1992) Molecular neuroanatomy of monoamine oxidases in human brainstem. Psychopharmacology [suppl] 106:21–23
Saavedra JM (1989) β-Phenylethylamine, phenylethanol-amine, tyramine and octopamine. Handbook of Experimental Pharmacology 90/II:181–210
Scheinin M, Koulu M, Karhuvaara S, Zimmer RH (1990) Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers. Life Sci 47:1491–1499
Scherschlicht R, Polc P, Schneeberger J, Steiner M, Haefely W (1982) Selective suppression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. In: Costa E, Racagni G (eds) Typical and atypical antidepressant. Raven Press, New York, pp 354–364
Schoerlin M-P, Da Prada M (1990) Species-specific biotransformation of moclobemide: a comparative study in rats and humans. Acta Psychiatr Scand [suppl] 360:108–110
Shih JC (1991) Molecular basis of human MAO-A and B. Neuropsychopharmacology 4:1–7
Trendelenberg U, Cassi L, Grohmann M, Lengeloh A (1987) The functional coupling of neuronal and extraneuronal transport with intracellular monoamine oxidase. J Neural Transm [suppl] 23:91–101
Trendelenburg U (1988) The extraneuronal uptake and metabolism of catecholamines. Handbook of Experimental Pharmacology 90/I:279–319
Weyler W, Hsu Y-PP, Breakefield XO (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47:391–417
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haefely, W., Burkard, W.P., Cesura, A.M. et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 106 (Suppl 1), S6–S14 (1992). https://doi.org/10.1007/BF02246225
Issue Date:
DOI: https://doi.org/10.1007/BF02246225